<p>|Recommendations|Certainty of evidence|Evidence report(s) of the following PICO(s)|Supp. App. 2|
|---|---|---|---|
|Subcutaneous nodules| | | |
|Methotrexate is conditionally recommended over alternative DMARDs for patients with subcutaneous nodules who have moderate-to-high disease activity.|Very low|PICO 64|p. 427|
|Switching to a non-methotrexate DMARD is conditionally recommended over continuation of methotrexate for patients taking methotrexate with progressive subcutaneous nodules.|Very low|PICO 65|p. 428|
|Pulmonary disease| | | |
|Methotrexate is conditionally recommended over alternative DMARDs for the treatment of inflammatory arthritis for patients with clinically diagnosed mild and stable airway or parenchymal lung disease who have moderate-to-high disease activity.|Very low|PICO 67|p. 430|
|Heart failure| | | |